Akero Shows More Strong Fibrosis Data, But Analysts Cite Safety Worry

 
• By Joseph Haas

Akero is developing weekly injectable efruxifermin for MASH with solid 96-week efficacy data and three Phase III studies underway. But will it find a treatment niche in a competitive space?

Female person holding red human liver model at white body
Akero's 96-week data shows sustained, expanded benefit in MASH

More from Strategy

More from Business